Header Logo

Connection

Robert Axtell to Humans

Back to Details
This is a "connection" page, showing publications Robert Axtell has written about Humans.
Robert Axtell
Connection Strength
0.557
Humans
  1. Biomarker panel increases accuracy for identification of an MS relapse beyond sNfL. Mult Scler Relat Disord. 2022 Jul; 63:103922.
    View in: PubMed
    Score: 0.046
  2. Interferon-ß Intensifies Interleukin-23-Driven Pathogenicity of T Helper Cells in Neuroinflammatory Disease. Cells. 2021 08 20; 10(8).
    View in: PubMed
    Score: 0.044
  3. Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE. Int J Mol Sci. 2021 Mar 13; 22(6).
    View in: PubMed
    Score: 0.042
  4. CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. Neurol Neuroimmunol Neuroinflamm. 2021 05; 8(3).
    View in: PubMed
    Score: 0.042
  5. Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. Nat Commun. 2020 06 05; 11(1):2856.
    View in: PubMed
    Score: 0.040
  6. Emerging Role of Follicular T Helper Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Int J Mol Sci. 2018 Oct 19; 19(10).
    View in: PubMed
    Score: 0.036
  7. Role of TFH Cells in Promoting T Helper 17-Induced Neuroinflammation. Front Immunol. 2018; 9:382.
    View in: PubMed
    Score: 0.034
  8. IFN-ß treatment requires B cells for efficacy in neuroautoimmunity. J Immunol. 2015 Mar 01; 194(5):2110-6.
    View in: PubMed
    Score: 0.028
  9. Type I interferons: beneficial in Th1 and detrimental in Th17 autoimmunity. Clin Rev Allergy Immunol. 2013 Apr; 44(2):114-20.
    View in: PubMed
    Score: 0.024
  10. Janus-like effects of type I interferon in autoimmune diseases. Immunol Rev. 2012 Jul; 248(1):23-35.
    View in: PubMed
    Score: 0.023
  11. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult Scler. 2012 Apr; 18(4):398-408.
    View in: PubMed
    Score: 0.023
  12. Interferon-ß exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011 Jun; 32(6):272-7.
    View in: PubMed
    Score: 0.021
  13. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med. 2010 Apr; 16(4):406-12.
    View in: PubMed
    Score: 0.020
  14. Gaining entry to an uninflamed brain. Nat Immunol. 2009 May; 10(5):453-5.
    View in: PubMed
    Score: 0.019
  15. Type 1 interferons cool the inflamed brain. Immunity. 2008 May; 28(5):600-2.
    View in: PubMed
    Score: 0.017
  16. Current and Future Biomarkers in Multiple Sclerosis. Int J Mol Sci. 2022 May 24; 23(11).
    View in: PubMed
    Score: 0.011
  17. Epstein Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J Autoimmun. 2020 01; 106:102332.
    View in: PubMed
    Score: 0.010
  18. B-lymphocyte-mediated delayed cognitive impairment following stroke. J Neurosci. 2015 Feb 04; 35(5):2133-45.
    View in: PubMed
    Score: 0.007
  19. Astrocytic TGF-ß signaling limits inflammation and reduces neuronal damage during central nervous system Toxoplasma infection. J Immunol. 2014 Jul 01; 193(1):139-49.
    View in: PubMed
    Score: 0.007
  20. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013 Nov; 14(11):1166-72.
    View in: PubMed
    Score: 0.006
  21. Interleukin 17F level and interferon ß response in patients with multiple sclerosis. JAMA Neurol. 2013 Aug; 70(8):1017-21.
    View in: PubMed
    Score: 0.006
  22. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest. 2013 Jun; 123(6):2447-63.
    View in: PubMed
    Score: 0.006
  23. Piet Mondrian's trees and the evolution in understanding multiple sclerosis, Charcot Prize Lecture 2011. Mult Scler. 2013 Jan; 19(1):5-14.
    View in: PubMed
    Score: 0.006
  24. Janus-like opposing roles of CD47 in autoimmune brain inflammation in humans and mice. J Exp Med. 2012 Jul 02; 209(7):1325-34.
    View in: PubMed
    Score: 0.006
  25. Serum IL-17F does not predict poor response to IM IFNß-1a in relapsing-remitting MS. Neurology. 2012 Aug 07; 79(6):531-7.
    View in: PubMed
    Score: 0.006
  26. Therapeutic effects of systemic administration of chaperone aB-crystallin associated with binding proinflammatory plasma proteins. J Biol Chem. 2012 Mar 23; 287(13):9708-9721.
    View in: PubMed
    Score: 0.006
  27. Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. Mol Ther. 2011 10; 19(10):1769-79.
    View in: PubMed
    Score: 0.005
  28. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-ß in multiple sclerosis. Sci Transl Med. 2011 Jul 27; 3(93):93ra68.
    View in: PubMed
    Score: 0.005
  29. Common variants in P2RY11 are associated with narcolepsy. Nat Genet. 2011 Jan; 43(1):66-71.
    View in: PubMed
    Score: 0.005
  30. Peroxisome proliferator-activated receptor delta limits the expansion of pathogenic Th cells during central nervous system autoimmunity. J Exp Med. 2010 Aug 02; 207(8):1599-608.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.